Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial

被引：1298

作者：

Gerstein, H. C. ^{[1
]}

Yusuf, S. ^{[1
]}

Holman, R. R. ^{[1
]}

Bosch, J. ^{[1
]}

Anand, S. ^{[1
]}

Avezum, A. ^{[1
]}

Budaj, A. ^{[1
]}

Chiasson, J. ^{[1
]}

Conget, I. ^{[1
]}

Dagenais, G. ^{[1
]}

Davis, M. ^{[1
]}

Diaz, R. ^{[1
]}

Dinccag, N. ^{[1
]}

Enjalbert, M. ^{[1
]}

Escalante, A. ^{[1
]}

Fodor, G. ^{[1
]}

Hanefeld, M. ^{[1
]}

Hedner, T. ^{[1
]}

Jolly, K. ^{[1
]}

Keltai, M. ^{[1
]}

Laakso, M. ^{[1
]}

Lanas, F. ^{[1
]}

Lonn, E. ^{[1
]}

McQueen, M. ^{[1
]}

Mohan, V. ^{[1
]}

Phillips, A. ^{[1
]}

Piegas, L. ^{[1
]}

Pirags, V. ^{[1
]}

Probstfield, J. ^{[1
]}

Shaw, J. ^{[1
]}

Schmid, I. ^{[1
]}

Teo, K. ^{[1
]}

Zimmet, P. ^{[1
]}

Zinman, B. ^{[1
]}

Gerstein, H. C. ^{[1
]}

Yusuf, S. ^{[1
]}

Bosch, J. ^{[1
]}

Pogue, J. ^{[1
]}

Sheridan, P. ^{[1
]}

Dinccag, N. ^{[1
]}

Hanefeld, M. ^{[1
]}

Hoogwerf, B. ^{[1
]}

Laakso, M. ^{[1
]}

Mohan, V. ^{[1
]}

Shaw, J. ^{[1
]}

Zinman, B. ^{[1
]}

Holman, R. R. ^{[1
]}

Diaz, R. ^{[1
]}

Ahuad Guerrero, R. ^{[1
]}

Albisu, J. ^{[1
]}

机构：

[1] Populat Hlth Res Inst, DREAM Project Off, Hamilton, ON L8L 2X2, Canada

来源：

LANCET | 2006年 / 368卷 / 9541期

基金：

加拿大健康研究院;

关键词：

D O I：

10.1016/S0140-6736(06)69420-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion. The aim of this study was to assess prospectively the drugs ability to prevent type 2 diabetes in individuals at high risk of developing the condition. Methods 5269 adults aged 30 years or more with impaired fasting glucose or impaired glucose tolerance, or both, and no previous cardiovascular disease were recruited from 191 sites in 21 countries and randomly assigned to receive rosiglitazone (8 mg daily; n=2365) or placebo (2634) and followed for a median of 3 years. The primary outcome was a composite of incident diabetes or death. Analyses were done by intention to treat. This trial is registered at ClinicalTrials.gov, number NCT00095654. Findings At the end of study, 59 individuals had dropped out from the rosiglitazone group and 46 from the placebo group. 306 (11.6%) individuals given rosiglitazone and 686 (26.0%) given placebo developed the composite primary outcome (hazard ratio 0.40, 95% CI 0.35-0.46; p<0.0001); 1330 (50.5%) individuals in the rosiglitazone group and 798 (30.3%) in the placebo group became normoglycaemic (1.71,1-57-1.87; p<0.0001). Cardiovascular event rates were much the same in both groups, although 14 (0.5%) participants in the rosiglitazone group and two (0.1%) in the placebo group developed heart failure (p=0.01). Interpretation Rosiglitazone at 8 mg daily for 3 years substantially reduces incident type 2 diabetes and increases the likelihood of regression to normoglycaemia in adults with impaired fasting glucose or impaired glucose tolerance, or both.

引用

页码：1096 / 1105

页数：10

共 28 条

[1] Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women [J].

Buchanan, TA ;

Xiang, AH ;

Peters, RK ;

Kjos, SL ;

Marroquin, A ;

Goico, J ;

Ochoa, C ;

Tan, S ;

Berkowitz, K ;

Hodis, HN ;

Azen, SP .

DIABETES, 2002, 51 (09) :2796-2803

[2] Prevention of cardiovascular outcomes in type 2 diabetes mellitus: Trials on the horizon [J].

Buse, JB ;

Rosenstock, J .

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2005, 34 (01) :221-+

[3] Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].

Chiasson, JL ;

Josse, RG ;

Gomis, R ;

Hanefeld, M ;

Karasik, A ;

Laakso, M .

LANCET, 2002, 359 (9323) :2072-2077

[4]

Diabetes Prevention Progam, 2005, DIABETES, V54, P1150

[5] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[6]

*DREAM TRIAL INV, IN PRESS N ENGL J ME

[7] β-cell mass dynamics in Zucker diabetic fatty rats -: Rosiglitazone prevents the rise in net cell death [J].

Finegood, DT ;

McArthur, MD ;

Kojwang, D ;

Thomas, MJ ;

Topp, BG ;

Leonard, T ;

Buckingham, RE .

DIABETES, 2001, 50 (05) :1021-1029

[8]

Genuth S, 2003, DIABETES CARE, V26, P3160

[9] Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial [J].

Gerstein, HC ;

Yusuf, S ;

Holman, R ;

Bosch, J ;

Pogue, J .

DIABETOLOGIA, 2004, 47 (09) :1519-1527

[10]

Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512

← 1 2 3 →